Sage Therapeutics (SAGE) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free SAGE Stock Alerts $13.69 +0.11 (+0.81%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineFY2025 Earnings Estimate for Sage Therapeutics, Inc. (NASDAQ:SAGE) Issued By William Blairamericanbankingnews.com - April 27 at 4:28 AMSage Therapeutics (NASDAQ:SAGE) Lifted to "Hold" at StockNews.comamericanbankingnews.com - April 27 at 2:50 AMSage Therapeutics (NASDAQ:SAGE) Rating Reiterated by Needham & Company LLCamericanbankingnews.com - April 27 at 1:54 AMSage Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lagsfinance.yahoo.com - April 26 at 8:20 PMBalancing Opportunity and Risk: Hold Rating on SAGE Therapeutics Amidst High-Stakes Catalysts and Financial Reassessmentmarkets.businessinsider.com - April 26 at 8:20 PMSage Therapeutics (NASDAQ:SAGE) Posts Quarterly Earnings Results, Misses Expectations By $0.17 EPSmarketbeat.com - April 26 at 5:03 PMSage Therapeutics (NASDAQ:SAGE) Price Target Cut to $25.00 by Analysts at HC Wainwrightmarketbeat.com - April 26 at 2:56 PMSage Therapeutics, Inc. (NASDAQ:SAGE) to Post FY2025 Earnings of ($7.01) Per Share, William Blair Forecastsmarketbeat.com - April 26 at 10:38 AMSAGE Therapeutics’ Zurzuvae Sales Exceed Expectations but Uncertainties Prompt Hold Ratingmarkets.businessinsider.com - April 26 at 7:51 AMSage Therapeutics (NASDAQ:SAGE) Shares Gap Up to $12.95americanbankingnews.com - April 26 at 5:34 AMHold Rating on SAGE Therapeutics Amid Limited Revenue Prospects and Pipeline Uncertaintymarkets.businessinsider.com - April 25 at 9:50 PMSage Therapeutics (NASDAQ:SAGE) Stock Price Up 5.5%marketbeat.com - April 25 at 5:36 PMSAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024investorplace.com - April 25 at 12:10 PMSage Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentationseekingalpha.com - April 25 at 12:04 PMSAGE Therapeutics, Inc. Q1 Loss decreases, but misses estimatesmarkets.businessinsider.com - April 25 at 11:48 AMSage Therapeutics Inc (SAGE) Q1 2024 Earnings: Mixed Results Amidst Pipeline Progressfinance.yahoo.com - April 25 at 11:48 AMSage Therapeutics (NASDAQ:SAGE) Earns Hold Rating from Needham & Company LLCmarketbeat.com - April 25 at 8:09 AMSage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progressbusinesswire.com - April 25 at 6:30 AMHere's what to expect from Sage Therapeutics's earnings reportmarkets.businessinsider.com - April 24 at 2:48 PMSage Therapeutics (NASDAQ:SAGE) Rating Lowered to Sell at StockNews.comamericanbankingnews.com - April 21 at 2:06 AMScotiabank Lowers Sage Therapeutics (NASDAQ:SAGE) Price Target to $19.00americanbankingnews.com - April 20 at 5:18 AMSage Therapeutics (NASDAQ:SAGE) Stock Rating Reaffirmed by Needham & Company LLCamericanbankingnews.com - April 20 at 5:18 AMSage Therapeutics (NASDAQ:SAGE) Price Target Cut to $17.00americanbankingnews.com - April 20 at 5:18 AMSage Therapeutics (NASDAQ:SAGE) Price Target Cut to $16.00americanbankingnews.com - April 20 at 4:42 AMWedbush Weighs in on Sage Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:SAGE)americanbankingnews.com - April 20 at 1:32 AMSage Therapeutics (NASDAQ:SAGE) Cut to "Sell" at StockNews.commarketbeat.com - April 19 at 11:04 PMQ1 2024 Earnings Estimate for Sage Therapeutics, Inc. (NASDAQ:SAGE) Issued By Wedbushmarketbeat.com - April 19 at 8:17 AMSage Therapeutics (NASDAQ:SAGE) Stock Rating Reaffirmed by HC Wainwrightamericanbankingnews.com - April 19 at 2:31 AMSage Therapeutics (NASDAQ:SAGE) Rating Reiterated by Wedbushamericanbankingnews.com - April 19 at 2:31 AMSage Therapeutics (NASDAQ:SAGE) Cut to Underperform at Bank of Americaamericanbankingnews.com - April 19 at 1:44 AMSage Therapeutics (NASDAQ:SAGE) Trading Up 6.2%marketbeat.com - April 18 at 4:33 PMB of A Securities Downgrades Sage Therapeutics (SAGE)msn.com - April 18 at 10:27 AMIn-Depth Examination Of 9 Analyst Recommendations For Sage Therapeuticsmarkets.businessinsider.com - April 18 at 10:27 AMSage Therapeutics (NASDAQ:SAGE) Given Hold Rating at Needham & Company LLCmarketbeat.com - April 18 at 8:23 AMSage Therapeutics (SAGE) Scheduled to Post Earnings on Thursdayamericanbankingnews.com - April 18 at 2:48 AMSage Therapeutics stock plunges 20 percent after Parkinson’s drug fails studymsn.com - April 17 at 6:40 PMWedbush Reiterates Neutral Rating for Sage Therapeutics (NASDAQ:SAGE)marketbeat.com - April 17 at 3:51 PMNeurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Databenzinga.com - April 17 at 1:38 PMBofA downgrades Sage to underperform, cites failed Parkinson's studymsn.com - April 17 at 1:38 PMNasdaq Down Over 1%; Sage Therapeutics Shares Plungemarkets.businessinsider.com - April 17 at 1:38 PMSage Stock Collapses To Record Low After Parkinson's Drug Misses Its Markfinance.yahoo.com - April 17 at 1:38 PMSage Therapeutics (NASDAQ:SAGE) Shares Gap Down to $15.63marketbeat.com - April 17 at 11:37 AMSage Therapeutics Hammered After Parkinson's Drug Misses The Markinvestors.com - April 17 at 8:46 AMSage Therapeutics Stops Further Development of Dalzanemdor in Parkinson's Diseasemarketwatch.com - April 17 at 8:38 AMSage Therapeutics Shares Sink Premarket After Setback in Development of Dalzanemdormarketwatch.com - April 17 at 8:38 AMSage Therapeutics' Dalzanemdor Phase 2 Study Fails To Meet Primary Endpointmarkets.businessinsider.com - April 17 at 8:38 AMSage drops after mid-stage setback for Parkinson’s disease candidatemsn.com - April 17 at 8:38 AMSage Therapeutics scraps Parkinson's drug development after treatment fails mid-stage studyreuters.com - April 17 at 8:38 AMSage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Diseasefinance.yahoo.com - April 17 at 8:38 AMSage Therapeutics (NASDAQ:SAGE) Hits New 1-Year Low at $15.06marketbeat.com - April 16 at 2:58 PM Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address This AI Trade Machine Made 1,729%* (With 89% Wins) (Ad)This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate… And a cumulative gain of 1729%. How does it all work? Click Here To Get Your Free Copy SAGE Media Mentions By Week SAGE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAGE News Sentiment▼-0.260.32▲Average Medical News Sentiment SAGE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAGE Articles This Week▼315▲SAGE Articles Average Week Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ABIVAX Société Anonyme News Today Innoviva News Today Zentalis Pharmaceuticals News Today Cassava Sciences News Today Arcutis Biotherapeutics News Today ARS Pharmaceuticals News Today 89bio News Today Liquidia News Today OPKO Health News Today MacroGenics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SAGE) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThey say it’s ‘unstoppable’ – How I made 43,509% Investing Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
